Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial (NCT06931340)
Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), uses surgery or drugs to lower the levels of male sex hormones in a man's body. This helps slow the growth of prostate cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Giving docetaxel in addition to the usual treatment of hormonal therapy and apalutamide may work better in treating patients with metastatic prostate cancer than the usual treatment alone.
Who can join: Review the eligibility criteria below.
Location: Banner University Medical Center - Tucson — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (200 Sites)
Showing the first 25 of 200 sites.
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente- Modesto MOB II — Modesto, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente-Oakland — Oakland, California
- Eisenhower Medical Center — Rancho Mirage, California
- Kaiser Permanente-Roseville — Roseville, California
- Kaiser Permanente Downtown Commons — Sacramento, California
- Kaiser Permanente-South Sacramento — Sacramento, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- Kaiser Permanente-San Francisco — San Francisco, California
- Kaiser Permanente-Santa Teresa-San Jose — San Jose, California
- Kaiser Permanente San Leandro — San Leandro, California
- Kaiser San Rafael-Gallinas — San Rafael, California
- Kaiser Permanente Medical Center - Santa Clara — Santa Clara, California
- Kaiser Permanente-Santa Rosa — Santa Rosa, California
- Kaiser Permanente-South San Francisco — South San Francisco, California
- Kaiser Permanente-Vallejo — Vallejo, California
- Kaiser Permanente-Walnut Creek — Walnut Creek, California
- Kaiser Permanente-Franklin — Denver, Colorado
- Shaw Cancer Center — Edwards, Colorado
📞 Contact the Study Coordinator
Phone: (773) 702-9171
Email: GUprotocols@alliancenctn.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Castration-Sensitive Prostate Carcinoma
- Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer — Portland, Oregon
- Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) — Phoenix, Arizona
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer — Duarte, California
- FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial — Chicago, Illinois
Explore by condition: All Castration-Sensitive Prostate Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.